Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

MTS business in Armenia sold $209.1 mln

3/7/24 MTSS

Head of Inter RAO will leave the company in the near future

3/7/24 IRAO

LSR majority shareholder Andrei Molchanov resigned as CEO

3/6/24 LSRG

Gazprom neft started development of the Chonskoye cluster

3/6/24 SIBN

HeadHunter redomiciles from Cyprus to Kaliningrad ATS

3/6/24 HEAD

Headhunter hints at dividends

3/6/24 HEAD

Headhunter has reported for 2023

3/6/24 HEAD

LSR minority shareholders may demand to buy back their securities at ₽1260 per share

3/6/24 LSRG

RusHydro reported for 2023 by IFRS

3/6/24 HYDR

Softline transferred 6% of shares to an institutional investor

3/6/24 SOFL